Citations

Institution: Mayo Clinic Clear

Showing 10 of 108083 citations.

Noncirrhotic Portal Hypertension: Current Concepts and Overview of Causes, Pathophysiology, and Imaging Findings
Borhani, Amir A. , Venkatesh, Sudhakar K. , Haghshomar, Maryam , Catania, Roberta , Boike, Justin , Thornburg, Bartley , Dasyam, Anil K. , Furlan, Alessandro , Miller, Frank H. , Pugliesi, Rosa Alba , Catania, Roberta , Boike, Justin R, Thornburg, Bartley , Dasyam, Anil K , Furlan, Alessandro , Miller, Frank H , Venkatesh, Sudhakar K

RadioGraphics | August 7, 2025 | Volume: 45 | Issue: 9 | Pages: No page available

10.1148/rg.240210 | PMID 40773371 Get It

Distinguishing noncirrhotic portal hypertension from cirrhosis is important because of differences in outcomes and management strategies, and imaging features such as liver morphology and the pattern of portal hypertension can aid in differentiation and should be carefully assessed.
Factors and Outcomes of Inappropriate Thyroid Ultrasonography
Larios, Felipe , Jacome, Cristian Soto , Ponce-Ponte, Oscar J., Maldonado, Kerly Guevara, Andrango, Luis Vilatuna, Proano, Ana Cristina , Loor-Torres, Ricardo , Zahidy, Misk Al, Claros, Ana Gabriela, Mulanovich, Katerina, Cabezas, Esteban , Wu, Yuqi , Bischoff, Lindsay , Ospina, Naykky Singh , Ospina, Naykky Singh , Larios, Felipe , Guevara, Kerly , Fan, Jungwei W, Al Zahidy, Misk, Branda, Megan E. , Singh Ospina, Naykky , Claros, Ana Gabriela , Toro-Tobón, David , Fan, Jungwei , Brito, Juan P.

JAMA Otolaryngology–Head & Neck Surgery | August 7, 2025 | Volume: 151 | Issue: 9 | Pages: 843

10.1001/jamaoto.2025.2049 | PMID 40773204 Get It

ImportanceThyroid cancer incidence has tripled in the past 3 decades, largely driven by increased detection of small, indolent papillary thyroid cancers. Overuse of thyroid ultrasonography (TUS) contributes to overdiagnosis, leading to unnecessary biopsies, procedures, and potential patient harm.ObjectiveTo evaluate the frequency of and factors associated with inappropriate TUS (iTUS) orders and assess related clinical outcomes.Design, Setting, and ParticipantsThis retrospective cohort study analyzed adult patients 18 years and older who underwent their first TUS from January 1, 2017, to December 30, 2021, at 4 Mayo Clinic sites. Patients with previous thyroid nodule, thyroid cancer, thyroid surgery, or TUS were excluded. Based on documented clinical indications, a validated natural language processing model classified TUS orders as appropriate or inappropriate. Data were analyzed from April 2024 to May 2025.ExposuresBaseline characteristics of patients, clinicians, and clinical encounters investigated for their association with an iTUS order.Main Outcomes and MeasuresThe primary outcome was the proportion of iTUS orders. Secondary outcomes included factors associated with iTUS (sociodemographic, clinical, order-specific, and clinician-related factors) and clinical outcomes following iTUS, including the detection of thyroid nodules, thyroid procedures, and thyroid cancer diagnoses.ResultsOf 11 442 included patients, 8422 (73.6%) were female, and the mean (SD) age was 57.3 (15.8) years with a mean (SD) body mass index (calculated as weight in kilograms divided by height in meters squared) of 29.7 (7.0). Among 11 442 TUS orders, 866 (7.6%) were classified as inappropriate. In multivariable analysis, younger age (age of 18 to 54 years vs older than 65 years; odds ratio [OR], 1.86; 95% CI, 1.56-2.22), hyperthyroidism (OR, 9.04; 95% CI, 6.75-12.11), ordering by nonendocrinology specialties (eg, oncology/hematology; OR, 3.43; 95% CI, 2.47-4.76), and orders not linked to an in-person appointment (eg, portal messages; OR, 2.42; 95% CI, 2.08-2.82) were strongly associated with increased odds of iTUS. Compared with appropriate TUS, iTUS led to lower rates of thyroid nodule detection (202 of 866 [23.3%] vs 6885 of 10 576 [65.1%]; OR, 0.16; 95% CI, 0.14-0.19), biopsies (89 [10.3%] vs 2647 [25.0%]; OR, 0.34; 95% CI, 0.27-0.43), partial thyroidectomies (14 [1.6%] vs 424 [4.0%]; OR, 0.39; 95% CI, 0.23-0.67), and confirmed thyroid cancer cases (16 [1.8%] vs 425 [4.0%]; OR, 0.45; 95% CI, 0.27-0.74).Conclusions and RelevanceIn this cohort study, approximately 1 in 13 TUS orders were inappropriate. iTUS was more common in younger patients, those with thyroid dysfunction, those not seen in person, and in those referred by nonendocrinology specialties. These findings highlight the need for targeted strategies to optimize TUS use and mitigate overdiagnosis and overtreatment.
Hemodynamics and Phosphodiesterase-5 Inhibitor Treatment Associated with Survival in Pulmonary Hypertension in Interstitial Lung Disease: A PVRI GoDeep Meta-Registry Analysis
Yogeswaran, Athiththan , Fünderich, Meike , Balasubramanian, Aparna , Konswa, Ziad , Kiely, David G. , Thenappan, Thenappan , Eichstaedt, Christina A. , Olschewski, Horst , Sweatt, Andrew J. , Zamanian, Roham T. , Giannakoulas, George , Elwing, Jean , Beckmann, Stephan, Olsson, Karen M. , Held, Matthias , Halank, Michael , Milger, Katrin , Pausch, Christine , Pittrow, David , Majeed, Raphael W. , Wilhelm, Jochen , Tello, Khodr , Seeger, Werner , Ghouleh, Imad Al , Sіrenko, Yu.M. , Balasubramanian, Aparna , Lawrie, Allan , Wilkins, Martin , Howard, Luke , Olschewski, Horst , Frantz, Robert, Stadler, Stefan , Hoeper, Marius M , Thenappan, Thenappan , Seeger, Werner , Yogeswaran, Athiththan , Kiely, David , Majeed, Raphael W , Hassoun, Paul M. , Saleh, Khaled, Grünig, Ekkehard , Wilkins, Martin R. , Kovács, Gábor , Cajigas, Héctor , Frantz, Robert P. , Sabbour, Hani Mohamed , Arvanitaki, Alexandra , Jose, Arun , Ewert, Ralf , Behr, Jürgen , Ghofrani, Hossein Ardeschir , Grimminger, Friedrich , Hoeper, Marius M.

American Journal of Respiratory and Critical Care Medicine | August 7, 2025 | Volume: 211 | Issue: 10 | Pages: 1855-1866

10.1164/rccm.202412-2371oc | PMID 40772955 Get It

Abstract Rationale Pulmonary hypertension (PH) in interstitial lung disease (ILD) lacks approved therapies. Objectives The Pulmonary Vascular Research Institute GoDeep metaregistry collects real-world data of patients with PH from international PH referral centers. Methods Patients with ILD-PH and relevant subgroups (idiopathic interstitial pneumonia [IIP], idiopathic pulmonary fibrosis [IPF]) were stratified by pulmonary vascular resistance (PVR). Kaplan-Meier survival analyses and adjusted Cox proportional hazards models were employed, additionally accounting for immortal time bias, sensitivity analyses, Heller explained relative risk statistics, and target trial emulation framework analysis. Measurements and Main Results Among 34,482 patients, 940 with hemodynamically fully characterized incident ILD-PH (median age, 67 [IQR, 59–74] yr) were identified. A total of 62% had severe ILD-PH with PVR >5 Wood units (WU) and poor survival rates (29% and 18% at 3 and 5 yr), significantly worse than patients with ILD-PH with PVR ≤5 WU and patients with pulmonary arterial hypertension. Survival was poorest in severe IPF-PH. A total of 59% of all patients ILD-PH received PH-targeted therapy, predominantly phosphodiesterase-5 inhibitors (PDE5is). PDE5i treatment was consistently associated with significantly improved survival in patients with severe PH (hazard ratios of 0.537 [0.370–0.781], 0.461 [0.233–0.913], and 0.435 [0.215–0.8] for IIP-PH, IPF-PH, and IIP-PH with nintedanib/pirfenidone background therapy), but not in patients with less severe hemodynamic impairment, supported by sensitivity analyses, Heller statistics, and target trial emulation framework analysis. The survival statistics of patients with PDE5i-treated IIP-PH or IPF-PH were validated in the independent COMPERA registry. Combination therapy with PDE5is and inhaled prostacyclin analogues was superior to monotherapy using PDE5is (hazard ratio, 0.341; 0.205–0.566). Conclusions Prognosis in ILD-PH was generally very poor and was related to PH severity. PDE5i treatment in severe IIP-PH and IPF-PH was associated with improved survival, which is to be further verified in controlled trials.
Overview of changes in the Clinical and Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility Testing: M100 32nd and 33rd editions
Schuetz, Audrey N. , Ferrell, Andrea , Hindler, Janet A., Humphries, Romney M. , Bobenchik, April M. , Humphries, Romney , Schuetz, Audrey N

Journal of Clinical Microbiology | August 7, 2025 | Volume: 63 | Issue: 9 | Pages: No page available

10.1128/jcm.01623-23 | PMID 40772786 Get It

ABSTRACT The Clinical and Laboratory Standards Institute Subcommittee on Antimicrobial Susceptibility Testing (AST) publishes annual updates to the M100 Performance Standards for Antimicrobial Susceptibility Testing . This important document contains key information critical to the laboratory’s performance of accurate and current AST. This minireview will highlight and provide supporting data for major changes in the M100 32nd and 33rd editions published in February 2022 and March 2023, respectively. New and revised breakpoints for gram-negative and gram-positive organisms are explained. Proper use of the restructured M100 Table 1 guidance for antimicrobial agents to be considered for testing and reporting is outlined. Reporting guidance for multidrug-resistant gram-negative bacilli is discussed. Other topics within this minireview include additional agents to test and report for direct blood disk diffusion of gram-negative bacilli and quality control range changes and troubleshooting. The minireview concludes with other issues under consideration by the AST Subcommittee.
Impact of Intensive Multimodal Treatment on the Outcomes of Patients With Anaplastic Thyroid Cancer
Alhayek, Bakr , Baidoun, Firas, Hadidi, Danny, Alhayek, Bakr , Alhaj Moustafa, Muhamad, Baidoun, Firas , Moustafa, Muhamad Alhaj , Abdel-Rahman, Omar Mohammed

American Journal of Clinical Oncology | August 7, 2025 | Volume: 49 | Issue: 3 | Pages: 136-146

10.1097/coc.0000000000001246 | PMID 40772694 Get It

Objectives: Anaplastic thyroid cancer (ATC) is a rare and aggressive type of thyroid malignancy with a very poor prognosis and outcome despite therapy. The rarity of this disease and the poor functional status of ATC patients limit the ability to conduct clinical trials, thus there is a lack of large, controlled trials to guide treatment and evaluate the benefit of combined modality therapy. Methods: The National Cancer Database (NCDB) was queried for patients diagnosed with ATC at age 18 or older between 2004 and 2018. After excluding patients with unknown number of treatment modalities, Charlson-Deyo score—a weighted summary of 17 chronic disease categories where higher scores denote greater baseline comorbidity burden—of 3 or more and patients lost for follow-up, we split the cohort into 3 groups according to the number of treatment modalities they received. Treatment modalities included surgery, radiation, and systemic therapy. Then, we evaluated the overall survival (OS) between the 3 groups. We studied the OS using Kaplan-Meier estimates and multivariate Cox regression analyses to evaluate factors associated with OS. In addition, propensity score matching (accounting for age, sex, race, Charlson-Deyo score, and clinical M stage) was used for more robust results. Results: A total of 3460 patients with ATC were included in the analysis, of which 1472 (42.5%) either received one type of therapy or did not receive any therapy (group 1), 1092 (31.6%) received bimodal therapy (group 2), and 896 (25.9%) received trimodal therapy (group 3). We found that group 3 had better OS compared with group 1 and group 2 (median OS 9.1 vs. 1.7 and 4.9 mo, respectively, with P <0.001 for all comparisons). Propensity score matching yielded 896 patients in each group. We found that group 3 had better OS compared with group 1 and group 2 (median OS 9.1 vs. 1.9 and 5.2 mo, respectively, with P <0.001 for all comparisons). Same trend was found in subgroup analysis when we split the cohort according to the metastatic status; in M0 group (median OS was 10.4 vs. 1.9 and 6.1 mo, respectively, with P <0.001 for all), in M1 group (median OS was 5.9 vs. 1.4 and 3.7 mo, respectively, with P <0.001 for all). Modality-specific analyses further demonstrated that surgery, radiation, and systemic therapy each independently prolonged OS in both M0 and M1 cohorts (all P <0.001). These individual benefits explain the additive advantage of trimodal therapy and underscore that offering at least one evidence-based modality is preferable when comprehensive treatment is infeasible. On multivariate analysis, group 1 and group 2 were associated with worse OS compared with trimodal treatment (HR: 2.721; 95% CI: 2.466-3.002 and HR: 1.434; 95% CI: 1.299-1.582, P <0.001 for all). Conclusions: Patients with ATC who were treated with intensive trimodal therapy had statistically significant improvement in OS compared with patients who received less intense therapy. This survival benefit was observed in both metastatic and nonmetastatic groups. Although we acknowledge the limitations of this retrospective analysis, our results showed the critical role of an intensive therapy approach in this aggressive malignancy.
Real-world Monitoring of ctDNA Reliably Predicts Cancer Recurrence and Treatment Efficacy in Patients with Resected Stages I-III Colon Cancer
Cohen, Stacey A. , Aushev, Vasily N. , Nagarajan, Arun , Wang, Chongkai , Alyunis, Fadhel, Tejani, Mohamedtaki Abdulaziz, Alqahtani, Ali , Marshall, John C., Chang, Jeremy , Manage, Kevin, George, Giby V., Malhotra, Meenakshi , Chandana, Sreenivasa R , Mehler, Shoshana , Somer, Bradley G. , Babadi, Ellie, Hanna, Diana L. , Chidharla, Anusha , Kasi, Anup , Vosoughi, Elham , Briski, Robert , Azzi, Georges, Katiyar, Vatsala , Sharma, Vivek R. , Shreenivas, Aditya , Fuqua, Jacob , Malla, Midhun , Polite, Blasé N. , Bent, Alisha H., Liu, Minetta C. , Aleshin, Alexey , Cohen, Stacey A , Laliotis, George , Jabbal, Iktej Singh , Fakih, Marwan , Sharif, Saima , Botta, Gregory P. , George, Giby V., Sharma, Shruti , Wu, Christina N. , Dayyani, Farshid , Pedersen, Katrina S. , Chan, Abigail Sy , Chakrabarti, Sakti , Bent, Alisha , Rabinowitz, Matthew , Jurdi, Adham Adel , Kopetz, Scott

Annals of Surgery | August 7, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/sla.0000000000006887 | PMID 40772634 Get It

Objective: In this study, we evaluate the utility of ctDNA analysis in a large cohort of patients for whom ctDNA testing was ordered commercially with real-world application. Summary Background Data: Circulating tumor DNA (ctDNA) has emerged as a prognostic and predictive biomarker for assessing post-surgical molecular residual disease (MRD) and response to treatment. Methods: A real-world data analysis was performed using commercial ctDNA testing (SignateraTM) from patients (N=795, n=5,971 plasma samples) with stage I-III colon cancer treated at multiple US institutions. The association of ctDNA detection within the MRD window, during surveillance, and the impact of ACT was correlated with patient outcomes. Results: ctDNA-positive patients during the MRD window and surveillance showed significantly shorter DFS compared to ctDNA-negative patients (hazard ratio (HR): 9.85, P<0.0001; HR: 26.91, P<0.0001). Multivariate analysis of the MRD window revealed ctDNA-positivity as the most significant factor associated with inferior DFS (adjHR: 7.7, P<0.001). MRD-positive patients who received ACT showed improved DFS compared to patients observed post-surgery (adjHR: 6.1, FDR adj P=0.0007). No ACT benefit was observed in MRD-negative patients (adj HR: 1.20, FDR adj P=0.768). On evaluating ctDNA dynamics from MRD to surveillance, patients who remained ctDNA-positive or converted from negative to positive showed a significantly inferior DFS (HR: 34.40, P<0.0001; HR: 13.65, P<0.0001) compared to persistently ctDNA-negative patients. Conclusions: Postsurgical ctDNA detection is prognostic of relapse and potentially predictive of ACT benefit in patients with resectable colon cancer, which may enable personalized surveillance, intervention, and/or trial options, ultimately improving patient outcomes.
Clonal Hematopoiesis Accelerates CKD Progression
Dumbrava, Mihai, Chowdhury, Raad

Kidney News | August 7, 2025 | Volume: 17 | Issue: 8 | Pages: 14

10.62716/kn.001022025 Get It

Clinical outcomes of switching from original omalizumab to an intended-copy biosimilar in chronic urticaria: a case series highlighting global regulatory discrepancies
Ahmed, S. K. Shahriar, Godse, Kiran, Singh, Apeksha, De, Abhishek , Chakraborty, Disha , Godse, Kiran Vasant , Singh, Apeksha

Clinical and Experimental Dermatology | August 7, 2025 | Volume: 51 | Issue: 5 | Pages: 895-897

10.1093/ced/llaf377 | PMID 40795385 Get It

Omalizumab, an anti-IgE monoclonal antibody, is a standard treatment for chronic spontaneous urticaria (CSU). In India, an ‘intended-copy biosimilar’ (ICB) was introduced in 2020, based on structural similarity, without clinical trials. This case series compares the efficacy and safety of ICBs with the original biologic. A retrospective review of nine patients with CSU (mean age 37.1 years) who switched from omalizumab to an ICB due to the unavailability of omalizumab. Disease control was assessed using the Urticaria Activity Score and the Urticaria Control Test. Findings highlight the need for rigorous biosimilar testing and standardized nomenclature to distinguish biosimilar types.
Menopause and Inflammatory Bowel Disease: A Systematic Review
Kale, Tanvi, Yoo, Linda , Kroeger, Ellie, Iqbal, Arwa, Kane, Sunanda V. , Shihab, Sara, Conley, Samantha , Kamp, Kendra , Conley, Samantha , Kroeger, Ellie, Iqbal, Arwa

Inflammatory Bowel Diseases | August 7, 2025 | Volume: 31 | Issue: 12 | Pages: 3443-3449

10.1093/ibd/izaf204 | PMID 41032035 Get It

Abstract Background Research is limited on the impacts of menopause, defined as the permanent cessation of ovarian function and decline of reproductive hormones, on gastrointestinal symptom severity and disease progression in women with inflammatory bowel disease (IBD). This review synthesizes current evidence on the impact of menopause, menopause transition, and hormonal therapy (HT) on disease activity, IBD and menopause symptom severity, and disease progression among individuals with IBD. Methods A systematic literature review was reported following PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines and preregistered at PROSPERO (CRD42024564901). Five databases were searched without date restrictions. Data extraction and risk-of-bias assessment were performed independently by multiple reviewers. Results were qualitatively synthesized. Results Of 1667 records, 15 studies met inclusion criteria (5 cohort, 3 case-control, 7 cross-sectional) with IBD sample sizes from 37 to 1367. Evidence on HT and IBD risk was mixed: some studies linked HT to increased ulcerative colitis risk while others found no significant association after adjusting for confounders. Women with IBD experience earlier menopause than healthy control subjects. While most women reported no change in IBD symptoms postmenopause, a minority reported symptom worsening. HT may reduce flare severity. Women with IBD reported more severe vulvovaginal symptoms and had distinct vaginal microbiome profiles compared with healthy control subjects. Conclusions Few studies have explored the relationship between menopause and IBD. There is a need for continued research on the relationship between IBD disease activity and menopause symptoms to create tailored interventions to improve women’s health with IBD across the lifespan.
EHR-Based CDS Tools Supporting Long-Term Implementation of Pharmacogenomics
Caraballo, Pedro J. , Wright, Jessica , Sutton, Joseph , Moyer, Ann M. , Sutton, Joseph A, Caraballo, Pedro J , Wright, Jessica A

Studies in Health Technology and Informatics | August 7, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3233/shti251118 | PMID 40776135 Get It

Pharmacogenomics (PGx) has the potential to improve prescribing practices. In 2012, our institution developed a multidisciplinary program to implement PGx-CDS to support the clinical practice. CDS has been implemented for 45 drug-gene interactions, in 42,000 patients with PGx tests results, and in 2023, approximately 9281 CDS interventions have triggered at the time of prescribing. The program has been successful.